Private practice with Dr Seth Bilazarian
View all posts »VerifyNow platelet test: Should we all be using it?
Dec 2, 2009 16:20 EST-
3Comments
-
Read later
An omnipresent possibility, platelet resistance is being studied more closely as witnessed by the POPULAR study published during AHA. New tests such as "VerifyNow" offer us onsite methods to screen for resistance, while double-dosing of clopidogrel—as shown in OASIS-7—and the approval of prasugrel have expanded our therapeutic options.
While we wait for definitive answers from the GRAVITAS study, how are you managing the risk of platelet resistance in your practice?
VerifyNow is a point of care test available for office or laboratory use and reimbursed by payers.
See:
POPULARity contest: For platelet function assays, what works, what doesn't
CURRENT OASIS-7: Benefit to doubling clopidogrel dose in ACS patients undergoing PCI
Scripps starts routine genetic testing for clopidogrel responsiveness
|
||||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
|
|
|
|||
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!












